<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bachmann LH</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>National Institutes of Health</funding><pagination>e624-e632</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7744987</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>71(10)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Antimicrobial resistance in Mycoplasma genitalium (MG), a cause of urethritis, is a growing concern. Yet little is known about the geographic distribution of MG resistance in the United States or about its associated clinical outcomes. We evaluated the frequency of MG among men with urethritis, resistance mutations, and posttreatment symptom persistence.&lt;h4>Methods&lt;/h4>We enrolled men presenting with urethritis symptoms to 6 US sexually transmitted disease (STD) clinics during June 2017-July 2018; men with urethritis were eligible for follow-up contact and, if they had persistent symptoms or MG, a chart review. Urethral specimens were tested for MG and other bacterial STDs. Mutations in 23S ribosomal ribonucleic acid (rRNA) loci (macrolide resistance-associated mutations</pubmed_abstract><journal>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</journal><pubmed_title>Prevalence of Mycoplasma genitalium Infection, Antimicrobial Resistance Mutations, and Symptom Resolution Following Treatment of Urethritis.</pubmed_title><pmcid>PMC7744987</pmcid><funding_grant_id>HHSN272000010</funding_grant_id><funding_grant_id>HHSN2722013000121</funding_grant_id><funding_grant_id>DIMD16-0039</funding_grant_id><pubmed_authors>Myler N</pubmed_authors><pubmed_authors>Sena AC</pubmed_authors><pubmed_authors>Bowden KE</pubmed_authors><pubmed_authors>MAGNUM Laboratory Working Group</pubmed_authors><pubmed_authors>Katz S</pubmed_authors><pubmed_authors>Wiesenfeld HC</pubmed_authors><pubmed_authors>Newman L</pubmed_authors><pubmed_authors>Nash E</pubmed_authors><pubmed_authors>Taylor SN</pubmed_authors><pubmed_authors>Danavall D</pubmed_authors><pubmed_authors>Bachmann LH</pubmed_authors><pubmed_authors>Fuchs R</pubmed_authors><pubmed_authors>Geisler WM</pubmed_authors><pubmed_authors>Manhart LE</pubmed_authors><pubmed_authors>McNeil CJ</pubmed_authors><pubmed_authors>Morris M</pubmed_authors><pubmed_authors>Kirkcaldy RD</pubmed_authors><pubmed_authors>Kersh E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prevalence of Mycoplasma genitalium Infection, Antimicrobial Resistance Mutations, and Symptom Resolution Following Treatment of Urethritis.</name><description>&lt;h4>Background&lt;/h4>Antimicrobial resistance in Mycoplasma genitalium (MG), a cause of urethritis, is a growing concern. Yet little is known about the geographic distribution of MG resistance in the United States or about its associated clinical outcomes. We evaluated the frequency of MG among men with urethritis, resistance mutations, and posttreatment symptom persistence.&lt;h4>Methods&lt;/h4>We enrolled men presenting with urethritis symptoms to 6 US sexually transmitted disease (STD) clinics during June 2017-July 2018; men with urethritis were eligible for follow-up contact and, if they had persistent symptoms or MG, a chart review. Urethral specimens were tested for MG and other bacterial STDs. Mutations in 23S ribosomal ribonucleic acid (rRNA) loci (macrolide resistance-associated mutations</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-04T14:15:21.577Z</modification><creation>2025-04-04T14:15:21.577Z</creation></dates><accession>S-EPMC7744987</accession><cross_references><pubmed>32185385</pubmed><doi>10.1093/cid/ciaa293</doi></cross_references></HashMap>